[1]孙 睿.地屈孕酮联合来曲唑对子宫内膜异位症患者性激素及CA125水平的影响[J].医学信息,2021,34(20):164-166.[doi:10.3969/j.issn.1006-1959.2021.20.044]
　SUN Rui.The Effect of Dydrogesterone Combined with Letrozole on the Levels of Sex Hormones andCA125 in Patients with Endometriosis[J].Medical Information,2021,34(20):164-166.[doi:10.3969/j.issn.1006-1959.2021.20.044]
点击复制

地屈孕酮联合来曲唑对子宫内膜异位症患者性激素及CA125水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年20期
页码:
164-166
栏目:
药物与临床
出版日期:
2021-10-20

文章信息/Info

Title:
The Effect of Dydrogesterone Combined with Letrozole on the Levels of Sex Hormones andCA125 in Patients with Endometriosis
文章编号:
1006-1959（2021）20-0164-03
作者:
孙 睿
天津市港口医院妇产科，天津 300456
Author(s):
SUN Rui
Department of Obstetrics and Gynecology,Tianjin Port Hospital,Tianjin 300456,China
关键词:
子宫内膜异位症; 地屈孕酮; 来曲唑; CA125; 性激素
Keywords:
Endometriosis; Dydrogesterone; Letrozole; CA125; Sex hormones
分类号:
R711.71
DOI:
10.3969/j.issn.1006-1959.2021.20.044
文献标志码:
A
摘要:
目的 研究地屈孕酮联合来曲唑对子宫内膜异位症（EM）患者性激素及糖类抗原 125（CA125）水平的影响。方法 选取2020年2月-2021年2月我院妇产科收治的90例EM病例，按照随机数字表法分为对照组与观察组，各45例。对照组仅采用地屈孕酮治疗，观察组在对照组基础上联合来曲唑治疗，比较两组临床疗效，并对其治疗前后的性激素水平[血清雌二醇（E2）、孕酮（P）]、CA125、炎症因子[白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）]以及血管内皮生长因子（VEGF）水平。结果 观察组治疗总有效率为95.56%，高于对照组的80.00%，差异有统计学意义（P＜0.05）；治疗后两组E2、P、CA125、IL-6、TNF-α、VEGF水平均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）。结论 地屈孕酮联合来曲唑治疗EM疗效确切，可有效调节患者性激素水平，同时降低其CA125、VEGF及炎性因子水平的表达。
Abstract:
Objective To study the effect of dydrogesterone combined with letrozole on the levels of sex hormones and carbohydrate antigen 125 (CA125) in patients with endometriosis (EM).Methods A total of 90 EM cases who were admitted to the Department of Obstetrics and Gynecology in our hospital from February 2020 to February 2021 were selected and divided into control group and observation group according to a random number table, with 45 cases in each group. The control group was only treated with dydrogesterone, and the observation group was combined with letrozole on the basis of the control group. The clinical effects, the levels of sex hormones before and after treatment [serum estradiol(E2), progesterone(P)], CA125, inflammatory factors [interleukin-6(IL-6), tumor necrosis factor-α(TNF-α)] and vascular endothelial growth factor(VEGF) levels were compared between the two groups.Results The total effective rate in the observation group was 95.56%, which was higher than 80.00% in the control group, and the difference was statistically significant (P<0.05); the levels of E2, P, CA125, IL-6, TNF-α, and VEGF in the two groups after treatment were lower than before treatment, and the observation group was lower than that in the control group, the difference was statistically significant (P<0.05).Conclusion Dydrogesterone combined with letrozole has a definite effect in the treatment of EM, which can effectively regulate the level of sex hormones and reduce the expression of CA125, VEGF and inflammatory factors.

参考文献/References:

[1]王燕,李明清,贾罗琦.来曲唑联合地屈孕酮治疗子宫内膜异位症的疗效及对患者性激素和CA125水平的影响[J].中国妇幼保健,2020,35(24):4699-4702.[2]陈媛媛,卢占斌.来曲唑对子宫内膜异位症患者内分泌激素的影响[J].中国性科学,2016,25(12):65-67.[3]刘中静.地屈孕酮联合来曲唑治疗子宫内膜异位症的效果分析[J].内蒙古医学杂志,2019,51(8):914-916.[4]王丽娜.地屈孕酮联合来曲唑治疗子宫内膜异位症的临床疗效分析[J].当代医学,2019,25(9):56-58.[5]中华医学会妇产科学分会子宫内膜异位症协作组.子宫内膜异位症的诊治指南[J].中华妇产科杂志,2015,50(3):161-169.[6]谭细凤,李怀芳,王玉凤,等.地屈孕酮联合来曲唑治疗对子宫内膜异位症患者性激素、炎性因子、CA125及VEGF的影响[J].基础医学与临床,2019,39(3):392-395.[7]杨慧.地屈孕酮联合来曲唑治疗子宫内膜异位症的临床效果分析[J].中外医学研究,2018,16(35):147-148.[8]Piedimonte S,Volodarsky-Perel A,Tannus S,et al.Pretreatment with a gonadotropin-releasing hormone agonist and an aromatase inhibitor may improve outcomes in IVF cycles of women with stage Ⅰ-Ⅱ endometriosis[J].F&S Science,2020,1(1):98-103.[9]任红娟,王学博,孙丽.地屈孕酮结合芳香化酶抑制剂治疗子宫内膜异位症的临床效果及对血清CA125、MMP-3、VEGF的影响[J].中国计划生育学杂志,2018,26(11):1044-1047.[10]耿喜玲.地屈孕酮联合来曲唑对子宫内膜异位症患者血清性激素水平及肿瘤标志物的影响[J].淮海医药,2018,36(1):57-59.[11]张素宁,张晓妮,牛芳蕾,等.左炔诺孕酮宫内缓释系统联合来曲唑治疗复发性子宫内膜异位症的疗效观察[J].广西医科大学学报,2017,34(11):1581-1584.[12]霍平,张晨光,李娟,等.来曲唑治疗子宫内膜异位症的实验研究[J].中国妇幼健康研究,2017,28(S4):146.[13]胡艳荣.地屈孕酮联合来曲唑对子宫内膜异位症患者E2、VEGF及CA125水平的影响[J].西藏医药,2017,38(5):39-41.[14]Siddiqa AJ,Shrivastava NK,Ali Mohsin ME,et al.Preparation of letrozole dispersed pHEMA/AAm-g-LDPE drug release system: In-vitro release kinetics for the treatment of endometriosis[J].Colloids Surf B Biointerfaces,2019(179):445-452.[15]曾庆红,赵红杉.地屈孕酮联合来曲唑治疗子宫内膜异位症的临床研究[J].现代药物与临床,2017,32(2):304-306.

相似文献/References:

[1]郭晓钰.子宫内膜异位症性不孕的中西医治疗[J].医学信息,2022,35(09):58.[doi:10.3969/j.issn.1006-1959.2022.09.014]
　GUO Xiao-yu.Chinese and Western Medicine Treatment of Endometriosis Infertility[J].Medical Information,2022,35(20):58.[doi:10.3969/j.issn.1006-1959.2022.09.014]
[2]刘秀娟,马艳华,马月巧,等.腹腔镜联合罗氏内异方治疗中、重度子宫内膜异位症 相关不孕的疗效观察[J].医学信息,2018,31(13):77.[doi:10.3969/j.issn.1006-1959.2018.13.022]
　LIU Xiu-juan,MA Yan-hua,MA Yue-qiao,et al.Observation on the Curative Effect of Laparoscopic Combined with Luo’s Internal Prescription for Severe Endometriosis Related Infertility[J].Medical Information,2018,31(20):77.[doi:10.3969/j.issn.1006-1959.2018.13.022]
[3]刘秀娟,刘 辉.子宫内膜异位症相关性不孕的诊断及治疗研究[J].医学信息,2018,31(14):35.[doi:10.3969/j.issn.1006-1959.2018.14.012]
　LIU Xiu-juan,LIU Hui.Diagnosis and Treatment of Endometriosis Related Infertility[J].Medical Information,2018,31(20):35.[doi:10.3969/j.issn.1006-1959.2018.14.012]
[4]孔俊沣,钟 雯,刘 嵩,等.MRI对卵巢子宫内膜异位囊肿的诊断价值[J].医学信息,2022,35(11):165.[doi:10.3969/j.issn.1006-1959.2022.11.044]
　KONG Jun-feng,ZHONG Wen,LIU Song,et al.The Diagnostic Value of MRI in Ovarian Endometriotic Cyst[J].Medical Information,2022,35(20):165.[doi:10.3969/j.issn.1006-1959.2022.11.044]
[5]李跃飞,郑晶晶,于聪祥.干细胞标记物Musashi-1与子宫内膜异位症关系的研究进展[J].医学信息,2018,31(23):48.[doi:10.3969/j.issn.1006-1959.2018.23.014]
　LI Yue-fei,ZHENG Jing-jing,YU Cong-xiang.Advances in Research on the Relationship between Cell Marker Musashi-1 and Endometriosis[J].Medical Information,2018,31(20):48.[doi:10.3969/j.issn.1006-1959.2018.23.014]
[6]樊 艺,王亚飞.参芪寿胎汤联合地屈孕酮治疗先兆流产合并绒毛膜下出血的临床研究[J].医学信息,2018,31(24):123.[doi:10.3969/j.issn.1006-1959.2018.24.035]
　FAN Yi,WANG Ya-fei.Clinical Study of Shenqi Shoutai Decoction Combined with Dydrogesterone in the Treatment of Threatened Abortion with Submacular Hemorrhage[J].Medical Information,2018,31(20):123.[doi:10.3969/j.issn.1006-1959.2018.24.035]
[7]邬素珍,许焕英,陈 玉,等.子宫内膜异位症痛经患者体质分布规律研究[J].医学信息,2019,32(15):80.[doi:10.3969/j.issn.1006-1959.2019.15.025]
　WU Su-zhen,XU Huan-ying,CHEN Yu,et al.Study on the Distribution Law of Dysmenorrhea in Patients with Endometriosis[J].Medical Information,2019,32(20):80.[doi:10.3969/j.issn.1006-1959.2019.15.025]
[8]邹万芹,孙立军.地屈孕酮联合低分子肝素钙治疗先兆流产患者的效果[J].医学信息,2019,32(14):151.[doi:10.3969/j.issn.1006-1959.2019.14.050]
　ZOU Wan-qin,SUN Li-jun.Effect of Dydrogesterone Combined with Low Molecular Weight Heparin Calcium in Patients with Threatened Abortion[J].Medical Information,2019,32(20):151.[doi:10.3969/j.issn.1006-1959.2019.14.050]
[9]陈 玉,邬素珍,朱巧玲.子宫内膜异位症痛经患者情志状况的临床观察[J].医学信息,2020,33(01):106.[doi:10.3969/j.issn.1006-1959.2020.01.032]
　CHEN Yu,WU Su-zhen,ZHU Qiao-ling.Clinical Observation of Emotional Status in Patients with Endometriosis Dysmenorrhea[J].Medical Information,2020,33(20):106.[doi:10.3969/j.issn.1006-1959.2020.01.032]
[10]李国馨.妇科因素所致慢性盆腔痛的研究[J].医学信息,2020,33(05):59.[doi:10.3969/j.issn.1006-1959.2020.05.018]
　LI Guo-xin.Study on Chronic Pelvic Pain Caused by Gynecological Factors[J].Medical Information,2020,33(20):59.[doi:10.3969/j.issn.1006-1959.2020.05.018]

更新日期/Last Update: 1900-01-01